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Cholesterol-Overloaded
Particles (HDL-C/HDL-P),
HDL-C, and HDL-P With
Increased Carotid Plaque
Progression Depend on
Adjusting for Each Other?Qi et al. (1) report that higher levels of the ratio of
high-density lipoprotein cholesterol (HDL-C)/high-
density lipoprotein particles (HDL-P) are associated
with carotid plaque (CP) progression in Chinese
adults (1). Their Central Illustration shows that within
each HDL-C tertile, the risk of CP progression in-
creases with lower HDL-P tertile, but that the relative
risk (1.55) is signiﬁcant only for those in the lowest
HDL-P tertile and highest HDL-C tertile versus the
highest tertiles of both HDL-P and HDL-C (1). Results
were similar in MESA (Multi-Ethnic Study of Athero-
sclerosis), with the thickest carotid intima-media
thickness in the lowest tertile of HDL-P but highesttertile of HDL-C (2). These results also agree with
the results of MESA (2) JUPITER (Justiﬁcation for the
Use of Statins in Prevention: An Intervention
Trial Evaluating Rosuvastatin) (3), HPS (Heart Pro-
tection Study), EPIC-Norfolk (European Prospective
Investigation into Cancer and Nutrition), IDEAL
(Incremental Decrease in End Points through
Aggressive Lipid Lowering), and other studies
that found that HDL-P is inversely associated
with atherosclerosis, coronary heart disease, and
cardiovascular disease (CVD) events, independent of
HDL-C, LDL-P, or apolipoprotein A-1 (apoA-1) and
apolipoprotein B (apoB) and also that higher HDL-C
(and larger mean HDL particle size) are not associ-
ated or are positively associated with atherosclerosis
and CVD when adjusted for levels of HDL-P, apoA-1,
LDL-P, and/or apoB. Yet, surprisingly, Qi et al. (1)
reports signiﬁcant associations of higher HDL-C/
HDL-P ratio, and lower HDL-C, but not HDL-P, with
CP progression and total plaque area. However, the
hazards ratios (HRs) for HDL-C/HDL-P, HDL-C and
HDL-P are only reported from models that simulta-
neously adjust for each other, as well as many corre-
lated covariates. Therefore, these HRs show only that
higher HDL-C/HDL-P is associated with CP progres-
sion at a given level of both HDL-C and HDL-P, but do
not show individual associations of HDL-C/HDL-P,
HDL-C, or HDL-P with CP progression. To fully un-
derstand these new results and their relation to pre-
vious studies, associations of HDL-C/HDL-P, HDL-C,
and HDL-P with CP should also be reported in separate
models, adjusted only for age, sex, smoking, diabetes,
body mass index, systolic blood pressure, with and
without LDL-P, and then adjusted for each other
separately (i.e., HDL-C/HDL-P and HDL-C, or HDL-P
with HDL-C).*Rachel H. Mackey, PhD, MPH
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A Measure of Reverse Cholesterol Transport
Rather Than HDL FunctionalityIn a recent issue of the Journal, Qi et al. (1) demon-
strated that high-density lipoprotein cholesterol
(HDL-C)/high-density lipoprotein particles (HDL-P)
ratio might predict atherosclerotic risk and might
explain why high plasma HDL-C levels have failed
to avoid ischemic events in some clinical trials.
Although the HDL-C/HDL-P ratio may provide a poor
and indirect metric for reverse cholesterol transport
(RCT), it is important to emphasize that it does not
reﬂect HDL functionality.
HDL-C/HDL-P ratio is a dynamic parameter, which
is determined primarily by the HDL-P turnover,
especially in a cardiovascular disease–free popula-
tion. High plasma HDL-P may thus be the major factor
predicting atherosclerotic risk, irrespective of plasma
HDL-C. High levels of plasma HDL-P may be achieved
either by increasing the synthesis rate of HDL-P or by
decreasing HDL-P catabolism. Under steady-state
conditions, the synthesis rate of a given protein
(such as apoprotein A-I) is equal to its turnover.
Therefore, an increase in HDL-P synthesis would be
more favorable for the overall process of RCT than
would the inhibition of HDL-P catabolism, because in
the latter mechanism, the HDL-P turnover may be
unaffected. Niacin, for instance, may increase plasma
HDL-C, at least in part, by preventing HDL-C from
being removed by the liver and therefore by blocking
HDL-P catabolism (2). This might explain, although
only in part, why the recent niacin trials did not
provide any cardiovascular beneﬁt.
However, any obstruction or limitation of HDL-P
turnover, either as a result of a reduced synthesis or
increased catabolism, may negatively affect RCT, and
thus lead to more tissue cholesterol deposition. This
afﬁrmation is supported by the data of Qi et al. (1)
showing no inverse relationship between HDL-C
levels and the risk of atherosclerosis progression
except for those in the lowest HDL-P subgroups (low
synthesis or high catabolism) (1).Finally, recent evidence also suggests that the
overall HDL-P is not as important as a determinant of
residual cardiovascular risk as the number of HDL-P,
which contain the lysosphingolipid sphingosine-
1-phosphate (S1P) (3). Pharmacological agents that
increase HDL-P levels by increasing its production in
the liver or that improve the functionality of existing
serum HDL-P, by increasing S1P uptake, for instance,
may be more beneﬁcial.*Emmanuel E. Egom, MSc, MD, PhD
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A Measure of Reverse Cholesterol Transport Rather Than
HDL FunctionalityThe main comment from Dr. Emmanuel E. Egom was
that the high-density lipoprotein cholesterol (HDL-C)/
high-density lipoprotein particle (HDL-P) ratio might
provide a poor and indirect metric for reverse
cholesterol transport (RCT) and did not reﬂect HDL
functionality. According to Dr. Egom’s comments,
HDL-P is a better indicator for the risk of atheroscle-
rosis than the HDL-C/HDL-P ratio, which is deter-
mined by HDL-P turnover. In response to Dr. Egom,
whether the HDL-C/HDL-P ratio in a cardiovascular
disease–free population is a poor or good metric for
RCT really needs further study, especially when there
is a lack of a measurable gold standard for the RCT
concept. If the RCT theory is true, we think that both
HDL-C and number of HDL-P, when used as a single
metric or biomarker, may not well reﬂect the func-
tionality of RCT for the following reasons: 1) the main
antiatherogenic function of RCT is to bring excess
